Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Nature Reviews Rheumatology

Volumn 16, Issue 3, 2020, Pages 155-166

  Schrezenmeier, Eva ^a   Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; CYCLIC GMP; CYTOCHROME P450 1A1; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; ANTIMALARIAL AGENT;

ABDOMINAL DISCOMFORT; ANTIGEN PRESENTING CELL; AUTOPHAGY (CELLULAR); BREAST FEEDING; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; EYE TOXICITY; HEART ARRHYTHMIA; HUMAN; IMMUNOMODULATION; NAUSEA; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPINAL CORD DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING; METABOLISM; RHEUMATOLOGY; TREATMENT OUTCOME;

ANTIMALARIALS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; HUMANS; HYDROXYCHLOROQUINE; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 85079461320     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/s41584-020-0372-x     Document Type: Review

References (156)

1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492–509 (2014).
2. Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736–745 (2019).
3. Pons-Estel, B. A. et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549–1557 (2018).
4. Gordon, C. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57, e1–e45 (2018).
5. Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296–1304 (2019).
6. Brito-Zeron, P., Ramos-Casals, M. & EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr. Opin. Rheumatol. 26, 520–527 (2014).
7. Vivino, F. B. et al. New treatment guidelines for Sjogren’s disease. Rheum. Dis. Clin. North. Am. 42, 531–551 (2016).
8. Ruiz-Irastorza, G. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20–28 (2010).
9. Ostensen, M. et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology 50, 657–664 (2011).
10. Akhavan, P. S. et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J. Rheumatol. 40, 831–841 (2013).
11. Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106–112 (2005).
12. Petri, M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13, 77–80 (2011).
13. Kingsbury, S. R. et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann. Intern. Med. 168, 385–395 (2018).
14. Lee, W. et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 70, 1320–1325 (2018).
15. Rempenault, C. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 77, 98–103 (2018).
16. Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009).
17. Flannery, E. L., Chatterjee, A. K. & Winzeler, E. A. Antimalarial drug discovery – approaches and progress towards new medicines. Nat. Rev. Microbiol. 11, 849–862 (2013).
18. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686–693 (2002).
19. Minie, M. et al. CANDO and the infinite drug discovery frontier. Drug Discov. Today 19, 1353–1363 (2014).
20. Paddon, C. J. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532 (2013).
21. Hale, V. et al. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. Am. J. Trop. Med. Hyg. 77, 198–202 (2007).
22. Mitchell, W. Natural products from synthetic biology. Curr. Opin. Chem. Biol. 15, 505–515 (2011).
23. Conway, D. J. Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet. 31, 97–107 (2015).
24. Karunamoorthi, K. Malaria vaccine: a future hope to curtail the global malaria burden. Int. J. Prev. Med. 5, 529–538 (2014).
25. de Beer, T. A. et al. Antimalarial drug discovery: in silico structural biology and rational drug design. Infect. Disord. Drug Targets 9, 304–318 (2009).
26. Vedadi, M. et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol. 151, 100–110 (2007).
27. Buckee, C. O. et al. Mobile phones and malaria: modeling human and parasite travel. Travel. Med. Infect. Dis. 11, 15–22 (2013).
28. Hay, S. I. et al. Big data opportunities for global infectious disease surveillance. PLoS Med. 10, e1001413 (2013).
29. Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert. Opin. Drug Saf. 16, 411–419 (2017).
30. Wang, S. Q. et al. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis. BMC Musculoskelet. Disord. 18, 186 (2017).
31. Manohar, S., Tripathi, M. & Rawat, D. S. 4-aminoquinoline based molecular hybrids as antimalarials: an overview. Curr. Top. Med. Chem. 14, 1706–1733 (2014).
32. Rainsford, K. D. et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231–269 (2015).
33. Witiak, D. T. et al. Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues. J. Med. Chem. 24, 712–717 (1981).
34. Tagoe, C. N. & Ofori-Adjei, D. Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Teratology 52, 137–142 (1995).
35. Ducharme, J. et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br. J. Clin. Pharmacol. 40, 127–133 (1995).
36. Tett, S. E. et al. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6, 355–359 (1994).
37. Tett, S. E. et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol. 27, 771–779 (1989).
38. Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5, S11–S15 (1996).
39. Cutler, D. J., MacIntyre, A. C. & Tett, S. E. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl. 24, 142–157 (1988).
40. McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11–18 (1983).
41. Fishbain, D. A. et al. Do some chronic pain patients with atypical facial pain overvalue and obsess about their pain? Psychosomatics 34, 355–359 (1993).
42. Tett, S. et al. Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. Agents Actions Suppl. 44, 145–190 (1993).
43. Tett, S. E., Day, R. O. & Cutler, D. J. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis – a cross sectional study. J. Rheumatol. 20, 1874–1879 (1993).
44. Collins, K. P., Jackson, K. M. & Gustafson, D. L. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J. Pharmacol. Exp. Ther. 365, 447–459 (2018).
45. Rynes, R. I. & Bernstein, H. N. Ophthalmologic safety profile of antimalarial drugs. Lupus 2, S17–S19 (1993).
46. Munster, T. et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1460–1469 (2002).
47. Carmichael, S. J., Charles, B. & Tett, S. E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 25, 671–681 (2003).
48. Spaldin, V. et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 38, 15–22 (1994).
49. Projean, D. et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab. Dispos. 31, 748–754 (2003).
50. Gil, J. P. & Gil Berglund, E. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 8, 187–198 (2007).
51. Projean, D. et al. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 33, 841–854 (2003).
52. Kim, K. A. et al. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch. Pharm. Res. 26, 631–637 (2003).
53. Li, X. Q. et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 59, 429–442 (2003).
54. Lee, J. Y. et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 68, 184–190 (2016).
55. Leden, I. Digoxin-hydroxychloroquine interaction? Acta Med. Scand. 211, 411–412 (1982).
56. Somer, M. et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 49, 549–554 (2000).
57. Kormelink, T. G. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69, 2137–2144 (2010).
58. Toimela, T., Tahti, H. & Salminen, L. Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res. 27, 150–153 (1995).
59. Bannwarth, B. et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet. 30, 194–210 (1996).
60. Carmichael, S. J. et al. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 29, 2077–2083 (2002).
61. van den Borne, B. E. et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J. Rheumatol. 25, 1493–1498 (1998).
62. Namazi, M. R. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus 18, 104–105 (2009).
63. Jallouli, M. et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 67, 2176–2184 (2015).
64. Ezra, N. & Jorizzo, J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin. Exp. Dermatol. 37, 327–334 (2012).
65. Yeon Lee, J. et al. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res. 69, 536–542 (2017).
66. Borden, M. B. & Parke, A. L. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 24, 1055–1063 (2001).
67. Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111–115 (2005).
68. Teng, Y. K. O. et al. An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology 57, 1707–1720 (2017).
69. Andreoli, L. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476–485 (2017).
70. Gotestam Skorpen, C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75, 795–810 (2016).
71. Izmirly, P. M. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126, 76–82 (2012).
72. Saxena, A. et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol. Rev. 22, 263–267 (2014).
73. Lisney, A. R. et al. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann. Rheum. Dis. 76, 1476–1480 (2017).
74. Friedman, D. et al. No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clin. Exp. Rheumatol. 35, 857–859 (2017).
75. Sammaritano, L. R. & Bermas, B. L. Rheumatoid arthritis medications and lactation. Curr. Opin. Rheumatol. 26, 354–360 (2014).
76. Circu, M. et al. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One 12, e0184922 (2017).
77. Mauthe, M. et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14, 1435–1455 (2018).
78. Frustaci, A. et al. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int. J. Cardiol. 157, 117–119 (2012).
79. Sundelin, S. P. & Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110, 481–489 (2002).
80. Ballabio, A. & Bonifacino J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101–118 (2019).
81. Lotteau, V. et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348, 600–605 (1990).
82. Ghislat, G. & Lawrence, T. Autophagy in dendritic cells. Cell Mol. Immunol. 15, 944–952 (2018).
83. Munz, C. Autophagy beyond intracellular MHC class II antigen presentation. Trends Immunol. 37, 755–763 (2016).
84. Ireland, J. M. & Unanue, E. R. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J. Exp. Med. 208, 2625–2632 (2011).
85. Ohkuma, S. & Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA 75, 3327–3331 (1978).
86. Rebecca, V. W. et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov. 9, 220–229 (2019).
87. Ma, C. et al. Identifying key genes in rheumatoid arthritis by weighted gene co-expression network analysis. Int. J. Rheum. Dis. 20, 971–979 (2017).
88. Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658–662 (2008).
89. Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794–4804 (2011).
90. Hacker, H. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230–6240 (1998).
91. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171–1177 (2005).
92. Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575–1585 (2005).
93. An, J. et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu. Rev. Med. 68, 317–330 (2017).
94. Zhang, X. et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 6, 421–430 (2014).
95. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013).
96. Shu, C., Li, X. & Li, P. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. Cytokine Growth Factor Rev. 25, 641–648 (2014).
97. An, J. et al. Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 194, 4089–4093 (2015).
98. van den Borne, B. E. et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J. Rheumatol. 24, 55–60 (1997).
99. Wallace, D. J. et al. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J. Rheumatol. 21, 375–376 (1994).
100. Wallace, D. J. et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2, S13–S15 (1993).
101. Hjorton, K. et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res. Ther. 20, 238 (2018).
102. Willis, R. et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21, 830–835 (2012).
103. Klinefelter, H. F. & Achurra, A. Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis. Scand. J. Rheumatol. 2, 177–182 (1973).
104. Dixon, J. S. et al. Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann. Rheum. Dis. 40, 480–488 (1981).
105. Wu, S. F. et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res. Ther. 19, 183 (2017).
106. Qushmaq, N. A. & Al-Emadi, S. A. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatol. 2014, 348726 (2014).
107. Nuri, E. et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65, 17–24 (2017).
108. Dadoun, S. et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 80, 29–33 (2013).
109. van den Hoek, J. et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol. Int. 37, 487–493 (2017).
110. Avina-Zubieta, J. A. et al. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res. 69, 849–856. (2017).
111. Tselios, K., Gladman, D. D., Su, J., Ace, O. & Urowitz, M. B. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J. Rheumatol. 44 1841–1849 (2017).
112. Padol, I. T. & Hunt, R. H. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology 49, 837–843 (2010).
113. Hage, M. P., Al-Badri, M. R. & Azar, S. T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther. Adv. Endocrinol. Metab. 5, 77–85 (2014).
114. Cansu, D. U. & Korkmaz, C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology 47, 378–379 (2008).
115. Fasano, S. et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol. 44, 1032–1038 (2017).
116. Towers, C. G. & Thorburn, A. Therapeutic targeting of autophagy. EBioMedicine 14, 15–23 (2016).
117. Rand, J. H. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 112, 1687–1695 (2008).
118. Jancinova, V., Nosal, R. & Petrikova, M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res. 74, 495–504 (1994).
119. Bertrand, E. et al. Antiaggregation action of chloroquine. Med. Trop. 50, 143–146 (1990).
120. Nosal, R., Jancinova, V. & Petrikova, M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb. Res. 77, 531–542 (1995).
121. Miranda, S. et al. Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction. PLoS One 14, e0212614 (2019).
122. Edwards, M. H. et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96, 4380–4384 (1997).
123. Lazarus, M. N. et al. Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 45, 1012–1015 (2006).
124. Srinivasa, A., Tosounidou, S. & Gordon, C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J. Rheumatol. 44, 398 (2017).
125. Abdel-Hamid, H., Oddis, C. V. & Lacomis, D. Severe hydroxychloroquine myopathy. Muscle Nerve 38, 1206–1210 (2008).
126. Jafri, K. et al. Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. Clin. Rheumatol. 36, 1437–1444 (2017).
127. Khosa, S. et al. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 38, 646–652 (2018).
128. Stein, M., Bell, M. J. & Ang, L. C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27, 2927–2931 (2000).
129. Dogar, M. U. et al. Hydroxychloroquine-induced restrictive cardiomyopathy: a case report. Postgrad. Med. J. 94, 185–186 (2018).
130. 99mTechnetium-labeled pyrophosphate scan for transthyretin-related cardiac amyloidosis. Circ. Cardiovasc. Imaging 11, e007059 (2018).
131. Chatre, C. et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 41, 919–931 (2018).
132. Costedoat-Chalumeau, N. et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology 46, 808–810 (2007).
133. Jorge, A. et al. Hydroxychloroquine retinopathy – implications of research advances for rheumatology care. Nat. Rev. Rheumatol. 14, 693–703 (2018).
134. Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386–1394 (2016).
135. Yusuf, I. H. et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32, 1168–1173 (2018).
136. MacIntyre, A. C. & Cutler, D. J. Kinetics of chloroquine uptake into isolated rat hepatocytes. J. Pharm. Sci. 82, 592–600 (1993).
137. Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284–3290 (2006).
138. Costedoat-Chalumeau, N. et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin. Pharmacol. Ther. 103, 1074–1082 (2018).
139. Bethel, M. et al. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. J. Investig. Med. 64, 908–910 (2016).
140. Sperati, C. J. & Rosenberg, A. Z. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney Int. 94, 634 (2018).
141. Yusuf, I. H., Lotery, A. J. & Ardern-Jones, M. R. Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. Br. J. Dermatol. 179, 995–996 (2018).
142. Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453–1460 (2014).
143. Costedoat-Chalumeau, N., Isenberg, D. & Petri, M. Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-215573 (2019).
144. Karasic, T. B. et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 5, 993–998 (2019).
145. Rosenfeld, M. R. et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10, 1359–1368 (2014).
146. Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369–1379 (2014).
147. Rangwala, R. et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10, 1391–1402 (2014).
148. Nti, A. A. et al. Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-dose hydroxychloroquine as treatment for advanced metastatic braf mutant melanoma: preliminary results from a phase I/II clinical treatment trial. Retina 39, 502–513 (2019).
149. Dorner, T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl. 77, 3–11 (2006).
150. Liang, N. et al. Multifaceted roles of ATM in autophagy: from nonselective autophagy to selective autophagy. Cell Biochem. Funct. 37, 177–184 (2019).
151. Bahia, M. S. et al. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cell Signal. 27, 1039–1055 (2015).
152. Khanfar, M. A. & Alqtaishat, S. Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses. Comput. Biol. Chem. 79, 147–154 (2019).
153. Kanvinde, S. et al. Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease. Acta Biomater. 82, 158–170 (2018).
154. Messai, A. in Emerging Research on Bioinspired Materials Engineering (ed. Bououdina, M.) 160–196 (IGI Global, 2016).
155. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs Accessdata.fda.gov https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=006002 (2014).
156. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs Accessdata.fda.gov https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768 (2014).